InvestorsHub Logo
Followers 10
Posts 778
Boards Moderated 0
Alias Born 03/18/2003

Re: scottsmith post# 126086

Tuesday, 10/24/2017 4:25:12 PM

Tuesday, October 24, 2017 4:25:12 PM

Post# of 459553

After all, avxl has cured the super responders and restores homeostasis.


I think bulls who push this point and sarcastic bears are missing the whole point. Anavex knew before it started the trial, that they will see some patients with good results and some with poor results. They never intended to use the results of the trial to "prove" efficacy. Their mission was to characterize the responders (good and bad) in an effort to lay out a proper pivotal trial that will take advantage of the feedback and increase chances of success. If this is achieved with 10% patients showing good results or with 80% patients showing good results, it would not matter. The questions to ask are: Is Anavex rounding up proper data that, when scrutinized, may help it run a successful pivotal trial?

IMHO
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News